STOCKHOLM, Feb. 11, 2026 — BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) is scheduled to release its financial report for the fourth quarter of 2025 (October – December) on Wednesday, February 18, 2026, at 08:00 a.m. CET.

Following the report’s publication, BioArctic extends an invitation to investors, analysts, and media representatives to attend a presentation on February 18 at 09:30 a.m. CET. The event will be led by CEO Gunilla Osswald and CFO Anders Martin-Löf, along with other company representatives, who will present and discuss the Q4 results, after which a question-and-answer session will be held.

To join the event via webcast, please use the link provided below. Participants will have the option to submit questions in writing during the webcast.

Webcast:

For those who prefer to participate by teleconference, registration is required via the link below. Upon registration, you will be provided with the necessary phone numbers and a conference ID. Questions can be asked live during the teleconference.

A recording of the webcast will be made available on BioArctic’s corporate website following the live presentation.  

For more information, please contact:
Oskar Bosson, VP Communications and Investor Relations
E-mail:
Tel: + 46 704 10 71 80

Jenny Ljunggren, External Communications and Investor Relations Manager
E-mail: 
Tel: +46 76 013 86 08

This information was submitted for publication at 08:30 a.m. CET on February 11, 2026.

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharmaceutical company dedicated to developing innovative treatments that can delay or halt the progression of neurodegenerative diseases. The company is the inventor of Leqembi® (lecanemab), the first therapy globally demonstrated to slow disease progression and reduce cognitive decline in patients with early Alzheimer’s disease. Leqembi was developed in collaboration with BioArctic’s partner Eisai, which handles all regulatory affairs and global commercialization. Beyond Leqembi, BioArctic maintains an extensive research pipeline featuring antibody treatments for Parkinson’s disease and ALS, alongside other Alzheimer’s disease initiatives. A number of these projects leverage the company’s proprietary BrainTransporter technology, designed to actively transport antibodies across the blood-brain barrier to improve treatment effectiveness. BioArctic’s class B share (BIOA B) is listed on Nasdaq Stockholm’s Large Cap segment. For more information, please visit .

This information was brought to you by Cision

The following files are available for download: